PMID- 31496264
OWN - NLM
STAT- MEDLINE
DCOM- 20200128
LR  - 20200128
IS  - 1938-2723 (Electronic)
IS  - 1076-0296 (Print)
IS  - 1076-0296 (Linking)
VI  - 25
DP  - 2019 Jan-Dec
TI  - In Vitro Assessment of von Willebrand Factor in Cryoprecipitate, Antihemophilic 
      Factor/VWF Complex (Human), and Recombinant von Willebrand Factor.
PG  - 1076029619873976
LID - 10.1177/1076029619873976 [doi]
LID - 1076029619873976
AB  - Patients with von Willebrand disease (VWD) often require treatment with 
      supplemental von Willebrand factor (VWF) prior to procedures or to treat 
      bleeding. Commercial VWF concentrates and more recently recombinant human VWF 
      (rVWF) have replaced cryoprecipitate as the mainstay of therapy. In comparison 
      with cryoprecipitate, the VWF content and multimer distribution under current 
      manufacturing processes of these commercial products has not been reported. We 
      measured the factor VIII (FVIII:C), VWF antigen (VWF:Ag), VWF collagen-binding 
      activity (VWF:CB), VWF platelet-binding activity by GPIbM enzyme-linked 
      immunosorbent assay (VWF:GPIbM), and percentage of high-molecular-weight (HMWM) 
      VWF in 3 pools of group A and O cryoprecipitate, 3 vials of VWF concentrate 
      (Humate-P), and 1 lot of rVWF (Vonvendi). We found that both group O and group A 
      cryoprecipitate have significantly higher ratios of VWF:GPIbM activity and 
      FVIII:C activity relative to VWF:Ag and have better preservation of HMWM than 
      Humate-P. Although not compared statistically, rVWF appears to have more HMWM VWF 
      and a higher ratio of VWF:GPIbM to VWF:Ag than Humate-P and cryoprecipitate. The 
      estimated acquisition cost for our hospital for treating one major bleeding 
      episode was more than 4-fold higher with Humate-P and 7- to 10-fold higher with 
      rVWF than with cryoprecipitate.
FAU - Colling, Meaghan E
AU  - Colling ME
AUID- ORCID: 0000-0002-8362-0613
AD  - Department of Pathology, Massachusetts General Hospital, Boston, MA, USA.
FAU - Friedman, Kenneth D
AU  - Friedman KD
AD  - Blood Research Institute, Versiti Blood Center of Wisconsin, Milwaukee, WI, USA.
FAU - Dzik, Walter H
AU  - Dzik WH
AD  - Department of Pathology, Massachusetts General Hospital, Boston, MA, USA.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Clin Appl Thromb Hemost
JT  - Clinical and applied thrombosis/hemostasis : official journal of the 
      International Academy of Clinical and Applied Thrombosis/Hemostasis
JID - 9508125
RN  - 0 (Recombinant Proteins)
RN  - 0 (cryoprecipitate coagulum)
RN  - 0 (von Willebrand Factor)
RN  - 839MOZ74GK (F8 protein, human)
RN  - 9001-27-8 (Factor VIII)
RN  - 9001-32-5 (Fibrinogen)
SB  - IM
MH  - Enzyme-Linked Immunosorbent Assay/methods
MH  - Factor VIII/analysis
MH  - Fibrinogen/analysis
MH  - Hemorrhage/drug therapy/economics
MH  - Humans
MH  - Recombinant Proteins/analysis
MH  - von Willebrand Diseases/*drug therapy/economics
MH  - von Willebrand Factor/*analysis
PMC - PMC6829641
OTO - NOTNLM
OT  - antihemophilic factor/VWF complex (human)
OT  - cryoprecipitate
OT  - high-molecular-weight von Willebrand multimers
OT  - recombinant von Willebrand factor
OT  - von Willebrand disease
COIS- Declaration of Conflicting Interests: The author(s) declared no potential 
      conflicts of interest with respect to the research, authorship, and/or 
      publication of this article.
EDAT- 2019/09/10 06:00
MHDA- 2020/01/29 06:00
PMCR- 2019/09/09
CRDT- 2019/09/10 06:00
PHST- 2019/09/10 06:00 [entrez]
PHST- 2019/09/10 06:00 [pubmed]
PHST- 2020/01/29 06:00 [medline]
PHST- 2019/09/09 00:00 [pmc-release]
AID - 10.1177_1076029619873976 [pii]
AID - 10.1177/1076029619873976 [doi]
PST - ppublish
SO  - Clin Appl Thromb Hemost. 2019 Jan-Dec;25:1076029619873976. doi: 
      10.1177/1076029619873976.